ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0814

Rare Variants of PAH Risk Genes Associate with a Distinct Vasculopathy Phenotype and Worse Outcomes in Patients with Systemic Lupus Erythematosus-associated Pulmonary Arterial Hypertension

Junyan Qian1, Xinzhuang Yang2, Yu Fang Ding3, qian wang1, Jiuliang Zhao1, Weida Liu4, Yongtai Liu5, Zhuang Tian5, Yanhong Wang6, Xiaojian Wang7, Mengtao Li1 and Xiaofeng Zeng8, 1Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China, 2Center for Bioinformatics, National Infrastructures for Translational Medicine, Institute of Clinical Medicine & Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 3Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, BEIJING, China (People's Republic), 4State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 5Department of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China, 6Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 7State Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, 8Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China

Meeting: ACR Convergence 2024

Keywords: Biomarkers, genetics, prognostic factors, pulmonary, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Abstracts: SLE – Diagnosis, Manifestations, & Outcomes I: Omics

Session Type: Abstract Session

Session Time: 1:00PM-2:30PM

Background/Purpose: Systemic lupus erythematosus (SLE)-associated pulmonary arterial hypertension (PAH) displays significant clinical heterogeneity; nevertheless, the underlying mechanisms remain unclear. Presently, more than twenty risk genes have been identified to be closely linked to the pathogenesis and prognosis of idiopathic and familial PAH. However, the contribution of rare variants of PAH risk genes to SLE-associated PAH remains largely unknown. Systemic lupus erythematosus (SLE)-associated pulmonary arterial hypertension (PAH) displays significant clinical heterogeneity; nevertheless, the underlying mechanisms remain unclear. Presently, more than twenty risk genes have been identified to be closely linked to the pathogenesis and prognosis of idiopathic and familial PAH. However, the contribution of rare variants of PAH risk genes to SLE-associated PAH remains largely unknown.

Methods: Based on the Chinese SLE Treatment and Research Group-PAH cohort, 241 patients with SLE-associated PAH were recruited and screened for rare deleterious variants in 28 PAH risk genes by whole exome sequencing. Clinical features, hemodynamic characteristics and outcomes were compared between variant carriers and noncarriers.

Results: Fifty-one patients (21.5%) carried rare deleterious variants of PAH risk genes. Compared to noncarriers, carriers had a shorter PAH duration from SLE onset (3.0 ± 3.1 vs. 5.3 ± 5.2 years, P=0.004), a higher proportion of PAH as the onset symptom of SLE (43.1% vs. 15.1%, P< 0.001) and lower SLE disease activity. Carrying rare variants of PAH risk genes was identified as an independent prognostic factor of mortality (hazard ratio [HR]=3.13, 95% CI, 1.10-8.97; P=0.005) and of reaching a low-risk profile of PAH (HR=0.56, 95% CI 0.34-0.94, P=0.027).

Conclusion: We showed for the first time that rare variants of PAH risk genes associated with a distinct vasculopathy phenotype and worse outcomes in patients with SLE-associated PAH, highlighting the significant clinical value in molecular classification.

Supporting image 1

Table 1. Comparison between carriers and noncarriers of variants of PAH risk genes in patients with SLE-associated PAH

Supporting image 2

Figure 1. Study flow chart. * The 28 PAH risk genes included BMPR2, EIF2AK4, TBX4, ATP13A3, GDF2, SOX17, AQP1, ACVRL1, SMAD9, ENG, KCNK3, CAV1, SMAD4, SMAD1, KLF2, BMPR1B, KCNA5, KDR, FBLN2, PDGFD, PTGIS, BMP10, ABCA3, ABCC8, GGCX, KLK1, TOPBP1 and SMAD5.

Supporting image 3

Figure 2. (A) A total of 237 patients with SLE-associated PAH were divided into two groups based on whether they carried rare variants in PAH risk genes. (B) Variant distribution matrix for 51 patients. (C) Pie chart representation of the different mutational types for 58 rare variants. (D) Variant classification according to ACMG Guidelines.


Disclosures: J. Qian: None; X. Yang: None; Y. Ding: None; q. wang: None; J. Zhao: None; W. Liu: None; Y. Liu: None; Z. Tian: None; Y. Wang: None; X. Wang: None; M. Li: None; X. Zeng: None.

To cite this abstract in AMA style:

Qian J, Yang X, Ding Y, wang q, Zhao J, Liu W, Liu Y, Tian Z, Wang Y, Wang X, Li M, Zeng X. Rare Variants of PAH Risk Genes Associate with a Distinct Vasculopathy Phenotype and Worse Outcomes in Patients with Systemic Lupus Erythematosus-associated Pulmonary Arterial Hypertension [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/rare-variants-of-pah-risk-genes-associate-with-a-distinct-vasculopathy-phenotype-and-worse-outcomes-in-patients-with-systemic-lupus-erythematosus-associated-pulmonary-arterial-hypertension/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rare-variants-of-pah-risk-genes-associate-with-a-distinct-vasculopathy-phenotype-and-worse-outcomes-in-patients-with-systemic-lupus-erythematosus-associated-pulmonary-arterial-hypertension/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology